Loading...
Indian Pharmaceutical Exporter · #1 for Insulin · $22.7M export value · DGFT Verified
Wockhardt Limited is the #1 Indian exporter of Insulin with $22.7M in export value and 454 verified shipments. Wockhardt Limited holds a 29.9% market share in Insulin exports across 25 countries. The company exports 10 pharmaceutical products worth $44.5M across 7 therapeutic categories.
| PHILIPPINES | $704.1K | 30 | 5.1% |
| VIETNAM | $485.6K | 14 | 3.5% |
| SRI LANKA | $390.8K | 16 | 2.9% |
| EL SALVADOR | $365.6K | 8 | 2.7% |
| INDONESIA | $350.0K | 7 | 2.6% |
| BOLIVIA | $264.4K | 7 | 1.9% |
Wockhardt Limited exports Insulin to 27 countries. The largest destination is THAILAND accounting for 52.6% of Wockhardt Limited's Insulin shipments, followed by MEXICO (8.4%) and PERU (6.5%). These destinations reflect Wockhardt Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BERLIN PHARMACEUTICALS INDUSTRY CO. | THAILAND | $3.4M | 103 |
| BERLIN PHARMACEUTICALS INDUSTRY CO | THAILAND | $2.5M | 82 |
| BERLIN PHARMACEUTICALS INDUSTRY CO, | THAILAND | $967.7K | 40 |
| HATAY PHARMACEUTICAL JOINT STOCK CO | VIETNAM, DEMOCRATIC REP. OF | $633.2K | 20 |
| PHARMARIS PERU S.A.C. | PERU | $623.9K | 18 |
| AYUSH PHARMA S.A DE C.V. | MEXICO | $600.0K | 12 |
| AMBICA INTERNATIONAL CORPORATION | PHILIPPINES | $554.1K | 24 |
| BIOMM S/A | BRAZIL | $482.7K | 11 |
| SISTEMAS AEREOS SA DE | EL SALVADOR | $300.0K | 6 |
| PT INFION | INDONESIA | $250.0K | 5 |
Wockhardt Limited supplies Insulin to 57 buyers globally. The largest buyer is BERLIN PHARMACEUTICALS INDUSTRY CO. (THAILAND), followed by BERLIN PHARMACEUTICALS INDUSTRY CO (THAILAND) and BERLIN PHARMACEUTICALS INDUSTRY CO, (THAILAND). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $52.4M worth of Insulin through 2,532 shipments from 188 suppliers to 111 countries, serving 384 buyers globally. Wockhardt Limited contributes $22.7M to this total, accounting for 29.9% of India's Insulin exports. Wockhardt Limited ships Insulin to 27 countries through 57 buyers.
Wockhardt Limited's average Insulin shipment value is $50.0K per consignment, based on 454 shipments totaling $22.7M. The largest destination is THAILAND (52.6% of Wockhardt Limited's Insulin exports).
Wockhardt Limited ranks #1 among 188 Indian Insulin exporters with a 29.9% market share. The top 3 exporters are WOCKHARDT LIMITED ($22.7M), M. J. BIOPHARM PRIVATE LIMITED ($15.2M), GLAND PHARMA LTD ($4.0M). Wockhardt Limited processed 454 shipments to 25 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| WINSULIN 30/70 100IU 5X3ML CARTRIDGE | $1.2M | 27 |
| VALVEY 100IU/ML, 10ML VIAL (INSULIN GLAR | $600.0K | 12 |
| WINSULIN 30/70 100IU 5X3ML CARTRIDGENOS | $496.2K | 10 |
| WINSULIN 30/70 100IU 10ML VIAL -GREEN CA | $362.9K | 8 |
| WINSULIN 30/70 100IU 10ML VIAL -GREEN CARD NO. 20956 DATED 28.03.2019 VALID UPTO 31.03.2024VLS | $358.8K | 9 |
| WINSULIN N 100IU 5X3ML CARTRIDGE | $338.1K | 10 |
| WINSULIN N 100IU 10ML VIAL -GREEN CARD N | $314.9K | 8 |
| WINSULIN 30/70 100IU 5X3ML (CARTRIDGE HU | $313.1K | 8 |
| GLARITUS DISPOPEN - 2 INSULIN GLARGINEINJECTION 100IU/ML | $250.0K | 5 |
| WINSULIN 30/70 100IU 10ML VIAL | $250.0K | 5 |
Wockhardt Limited exports 224 distinct Insulin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is WINSULIN 30/70 100IU 5X3ML CARTRIDGE with 27 shipments worth $1.2M.
What Wockhardt Limited must comply with to export Insulin to its top destination countries
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | WOCKHARDT LIMITED ★ | $22.7M | 454 | 25 | $50.0K |
| 2 | M. J. BIOPHARM PRIVATE LIMITED | $15.2M | 303 | 23 | $50.0K |
| 4 | GLAND PHARMA LTD | $4.0M | 81 | 4 | $50.0K |
Wockhardt Limited ranks #1 among 188 Indian Insulin exporters. Average shipment value of $50.0K compared to the market average of $278.5K. The closest competitors by value are M. J. BIOPHARM PRIVATE LIMITED and GLAND PHARMA LTD.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 704 | 27.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 646 | 25.5% |
| Bombay Air | 177 | 7.0% |
| Bombay Air Cargo | 123 | 4.9% |
| NHAVA SHEVA SEA (INNSA1) | 108 | 4.3% |
| DELHI AIR | 76 | 3.0% |
| BANGALORE ACC (INBLR4) | 69 | 2.7% |
| JNPT | 68 | 2.7% |
Wockhardt Limited also exports these diabetes & endocrine products. Each links to the detailed product page.
Wockhardt's export operations are influenced by various geopolitical factors. The Israel-Iran conflict has disrupted Red Sea shipping routes, leading to increased shipping costs and extended transit times for Indian pharmaceutical exporters. These disruptions pose challenges for time-sensitive products, particularly those requiring stringent cold-chain logistics. (pharmaceuticalcommerce.com)
In the U.S., recent tariff policies have introduced additional complexities. In August 2025, the U.S. imposed broad tariffs on imports from over 60 countries, including India, with rates reaching up to 39%. These tariffs have impacted nearly 55% of India's exports to the U.S., placing Indian pharmaceutical companies at a competitive disadvantage. (apnews.com)
Conversely, the U.S.-China trade tensions have created opportunities for Indian pharmaceutical companies to fill supply gaps in the American market. However, the overall impact of U.S. tariff policies remains a significant concern for exporters like Wockhardt.
In the European Union, compliance with the Falsified Medicines Directive (FMD) has become increasingly stringent. Indian exporters must invest in advanced serialization and traceability systems to meet these requirements, ensuring the authenticity and safety of pharmaceutical products in the EU market.
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA and the European Medicines Agency (EMA) enforcing stringent quality standards. India, housing over 600 U.S. FDA-approved manufacturing sites, faces challenges in maintaining compliance. In 2023, the U.S. FDA conducted more than 200 inspections in India, with plans to increase this number in 2024. (fact.net.in)
For Wockhardt, adherence to Good Manufacturing Practices (GMP) and other regulatory standards is crucial to sustain its export operations. The company's strategic focus on high-impact areas necessitates continuous investment in quality control systems and infrastructure to meet evolving global standards.
Wockhardt Limited exports 10 products worth $44.5M. Beyond Insulin, top products include Codeine, Levothyroxine, Ibuprofen, Prednisolone, Folic. View the complete Wockhardt Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Insulin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 111+ countries, 384+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Wockhardt Limited's Insulin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Wockhardt Limited
Full Company Profile →
10 products · $44.5M total trade · 7 categories
Access shipment-level records, pricing trends, and buyer contacts for Wockhardt Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Insulin. For current shipment-level data, contact TransData Nexus.